Lowest Price Guaranteed
From USD
3,499
Published
March 2018
Pages
520
View Count
3378
Trends related to manufacturing have changed completely in the last 10-12 years. Large pharma companies are rapidly expanding their offerings by acquiring smaller companies. At the same time, some players are transferring their R&D and manufacturing operations to smaller players, while themselves operating as virtual companies.
-President and CEO, US based mid-sized CMO
The present pipeline of pharmaceutical products is increasingly complex and requires specialized facilities, equipment and operational expertise. Small molecule drugs account for nearly 90% of the therapeutics in the pharmaceutical market. In fact, in 2017, FDA’s Center for Drug Evaluation and Research approved 34 small molecule drugs; this represents an annual growth of nearly 56%, signifying the growing importance of contract manufacturing in the overall pharmaceutical industry. The costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. The aforementioned constraints have led many of the smaller players in the industry and, at times, certain pharma giants as well, to outsource a significant part of their business operations to contract service providers. Third-party service providers are known to offer significant cost-benefits, access to larger production capacities and reductions in time-to-market.
Over the years, the contract manufacturing market has grown into a prominent and promising segment of the overall pharmaceutical industry. Since 2000, close to 150 new CMOs have been established, offering cost-efficient solutions to several stakeholders in the industry.
The current global CMO market is highly fragmented but characterized by multiple acquisitions and mergers as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to start offering end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings.
Despite the fact that the pharmaceutical sector is amongst the most highly regulated industries, we expect the demand for core competencies to continue to drive sponsor companies to outsource various parts of their manufacturing operations. Amidst tough competition, the availability of advanced tools and technologies is an important differentiating factor and will grant a competitive edge to certain CMOs over other stakeholders in the industry. However, given the ongoing innovation in production technologies and the steadily evolving pipeline of small molecules, the pressure on the contract manufacturing industry is expected to increase in the coming years. This is likely to require CMOs to devise and implement different business strategies and models in order to cope with the evolving demand.
Scope of Report
The ‘Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028’ report provides a comprehensive study on the current scenario of contract manufacturing services related to pharmaceutical products. The study features an in-depth analysis, highlighting the capabilities of a diverse set of pharmaceutical CMOs. Amongst other elements, the report features:
One of the key objectives of this report was to evaluate the current opportunity and the future potential of the pharmaceutical contract manufacturing market over the coming decade. Based on various parameters, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2028. In addition, we have provided the likely distribution of the market based on [A] type of business segment (API and FDF), [B] regional evolution of the market covering North America (the US, Canada and Mexico), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, Australia and rest of Asia) and rest of the world, [C] type of API product (branded and generic) within the aforementioned regions, [D] type of FDFs manufactured (solids, liquids / semi-solids and injectables), [E] type of packaging forms (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe), [F] scale of API manufacturing (clinical, commercial, and both) and [G] size of manufacturers (small sized, mid-sized, large and very large companies). To account for the uncertainties associated with the growth of pharmaceutical contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. This enabled us to solicit inputs on upcoming opportunities and challenges that were considered to develop estimates for a more inclusive growth. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of pharmaceutical contract manufacturing market, in the short-mid and long term.
Chapter 3 is a general introduction to various type of manufacturers in the pharmaceutical market. It features a brief overview of the concept of contract manufacturing and a general discussion on the evolution of the contract services in the pharmaceutical industry. It also includes a detailed discussion on the need for outsourcing in this domain. Further, we have provided a brief overview of contract manufacturing models that have been adopted in the pharmaceutical industry, till date. We have also presented an exhaustive list of services offered by CMOs; the chapter concludes with a discussion on the challenges associated with the market.
Chapter 4 provides a comprehensive view on the global landscape of pharmaceutical CMOs. It includes information related to over 500 CMOs that are currently active in the pharmaceutical industry. It features an in-depth market review, including regional distribution, analysis by company size and year of establishment, type of business segments, type of FDFs manufactured, scale of operation, type of service(s) offered, location of manufacturing facilities and different types of primary packaging forms being manufactured.
Chapter 5 featuresa detailed discussion on the guidelines laid down by major regulatory bodies across different countries. The report also includes an assessment of over 500 CMOs related to the operational approvals and certifications received from various regulatory bodies, along with a schematic world map representation, highlighting the relative popularity (in terms of the number of companies that are operating in compliance to the guidelines laid down by each regulatory authority) of the key regulatory bodies across the globe. In addition, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies across the globe.
Chapter 6 features detailed profiles of some of the key players that are active in the pharmaceutical contract manufacturing market and are acting as one-stop-shops. Each profile presents a brief overview of the company, its financial information (if available) , details related to its service(s) portfolio, manufacturing facilities and capabilities, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.
Chapter 7 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it provides an overview of the current biopharmaceutical contract manufacturing landscape, featuring a list of over 200 CMOs that are offering contract manufacturing services for large molecules / biologics.
Chapter 8 presents a collection of key insights derived from the study. It includes a heat map analysis, highlighting the number of integrated players based on the location of their headquarters, year of establishment and number of employees. The chapter also features a geographical landscape analysis, wherein pharmaceutical CMOs having a relatively wide geographical reach, are highlighted. For this analysis, we have also highlighted the geographical locations of the aforementioned companies on a world map. In addition, the chapter includes a schematic grid analysis, featuring the distribution of pharmaceutical CMOs based on location of their headquarters, number of employees and the type of business operations (API / FDF / both).
Chapter 9 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of pharmaceutical products. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small-sized, mid-sized, large and very large CMOs, distributed across their respective facilities. The results of this analysis were used to establish an accurate opinion on outsourcing capabilities of the CMOs across different geographies / regions and scales of operation (clinical, commercial and both). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.
Chapter 10 provides a comprehensive market forecast analysis, highlighting the future potential of pharmaceutical contract manufacturing till the year 2028. It features the likely distribution of the market based on [A] type of business segment (API and FDF), [B] region (North America, Europe, Asia-Pacific and rest of the world) and further distribution by major countries within the aforementioned regions, [C] type of API product (branded and generic) within the aforementioned regions, [D] type of FDFs manufactured (solids, liquids / semi-solids and injectables), [E] type of packaging forms (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe), [F] scale of API manufacturing (clinical, commercial, and both) and [G] size of manufacturers (small sized, mid-sized, large and very large-companies).
Chapter 11 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under a comprehensive SWOT framework. The chapter also highlights a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall pharmaceutical industry.
Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters. It also provides a brief overview of some of the upcoming future trends, which, we believe, are likely to influence the growth of pharmaceutical CMOs in the foreseen future.
Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Scott Goldstein (Associate Director, Drug Product Manufacturing, Ajinomoto Althea), Thomas Früh (CEO, Bachem), Piyush Desai (Director, Operations, Sovereign Pharma), Claire Otjes (Assistant Manager, Marketing, Batavia Biosciences), Dietmar Katinger (CEO, Polymun Scientific), Birgit Schwab (Senior Manager, Strategic Marketing, Rentschler Biopharma), Sebastian Schuck (Head, Business Development, WACKER Biotech), Bhaskar Venepalli (President and CEO, CiVentiChem), Roberto Margarita (Director, Business Development, CordenPharma), Allison Vavala (Senior Manager, Business Development, Helsinn Group), Kevin Daley (Director, Pharmaceuticals Marketing, Novasep).
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 15 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Manufacturers in the Contract Manufacturing Industry
3.3. An Overview of the Pharmaceutical Contract Manufacturing Industry
3.4. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1. Traditional CMOs
3.4.2. Modern CMOs
3.5. The Need for Outsourcing in the Pharmaceutical Industry
3.6. Recent Trends in the Pharmaceutical Contract Manufacturing Industry
3.6.1. Tactical Partnership
3.6.2. Integrated End-to-End Business Model
3.6.3. Strategic Long-Term Alliance
3.6.4. Flexible Short-Term Partnership
3.6.5. Software Service Providers
3.7. Services Offered by CMOs
3.8. Selecting a CMO Partner
3.9. Risks and Challenges in Contract Manufacturing Industry
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical CMOs: List of Industry Players
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Type of Business Segment
4.2.5. Distribution by Type of FDF Offered
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Type of Service Offering
4.2.8. Distribution by Location of Manufacturing Facilities
4.2.9. Distribution by Type of Primary Packaging Form Offered
5. REGULATORY LANDSCAPE FOR PHARMACEUTICAL CONTRACT MANUFACTURERS
5.1. Chapter Overview
5.2. Regulatory Guidelines in North America
5.2.1. The US Scenario
5.2.2. Canadian Scenario
5.3. Regulatory Guidelines in Europe
5.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
5.4.1. Chinese Scenario
5.4.2. Indian Scenario
5.4.3. Japanese Scenario
5.4.4. South Korean Scenario
5.4.5. Australian Scenario
5.4.6. Brazilian Scenario
5.5. Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
5.6. Bubble Analysis: Regional Regulatory Summary
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Importance of One-Stop-Shops
6.3. Company Profiles of One-Stop-Shops
6.4. Players in North America
6.4.1. Albany Molecular Research (AMRI)
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Financial Information
6.4.1.4. Manufacturing Capabilities and Facilities
6.4.1.5. Recent Developments
6.4.1.6. Future Outlook
6.4.2. Catalent Pharma Solutions
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Financial Information
6.4.2.4. Manufacturing Capabilities and Facilities
6.4.2.5. Recent Developments
6.4.2.6. Future Outlook
6.4.3. DPT Laboratories
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments
6.4.3.5. Future Outlook
6.4.4. Thermo Fisher Scientific (Through Acquisition of Patheon)
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Financial Information
6.4.4.4. Manufacturing Capabilities and Facilities
6.4.4.5. Recent Developments
6.4.4.6. Future Outlook
6.5. Players in Europe
6.5.1. Aenova Group
6.5.1.1. Company Overview
6.5.1.2. Service Portfolio
6.5.1.3. Financial Information
6.5.1.4. Manufacturing Capabilities and Facilities
6.5.1.5. Recent Developments
6.5.1.6. Future Outlook
6.5.2. Almac Group
6.5.2.1. Company Overview
6.5.2.2. Service Portfolio
6.5.2.3. Recent Developments
6.5.2.4. Future Outlook
6.5.3. CordenPharma
6.5.3.1. Company Overview
6.5.3.2. Service Portfolio
6.5.3.3. Manufacturing Capabilities and Facilities
6.5.3.4. Recent Developments
6.5.3.5. Future Outlook
6.5.4. Fresenius Kabi
6.5.4.1. Company Overview
6.5.4.2. Service Portfolio
6.5.4.3. Financial Information
6.5.4.4. Manufacturing Capabilities and Facilities
6.5.4.5. Recent Developments
6.5.4.6. Future Outlook
6.5.5. Glatt®
6.5.5.1. Company Overview
6.5.5.2. Service Portfolio
6.5.5.3. Manufacturing Capabilities and Facilities
6.5.5.4. Recent Developments
6.5.5.5. Future Outlook
6.5.6. Groupe SYNERLAB
6.5.6.1. Company Overview
6.5.6.2. Service Portfolio
6.5.6.3. Manufacturing Capabilities and Facilities
6.5.6.4. Future Outlook
6.5.7. Hovione
6.5.7.1. Company Overview
6.5.7.2. Service Portfolio
6.5.7.3. Manufacturing Capabilities and Facilities
6.5.7.4. Recent Developments
6.5.7.5. Future Outlook
6.5.8. Recipharm
6.5.8.1. Company Overview
6.5.8.2. Service Portfolio
6.5.8.3. Financial Information
6.5.8.4. Manufacturing Capabilities and Facilities
6.5.8.5. Recent Developments
6.5.8.6. Future Outlook
6.5.9. Siegfried
6.5.9.1. Company Overview
6.5.9.2. Service Portfolio
6.5.9.3. Financial Information
6.5.9.4. Manufacturing Capabilities and Facilities
6.5.9.5. Recent Developments
6.5.9.6. Future Outlook
6.6. Players in Asia-Pacific
6.6.1. CMIC Group
6.6.1.1. Company Overview
6.6.1.2. Service Portfolio
6.6.1.3. Financial Information
6.6.1.4. Manufacturing Capabilities and Facilities
6.6.1.5. Recent Developments
6.6.1.6. Future Outlook
6.6.2. Nectar Lifesciences
6.6.2.1. Company Overview
6.6.2.2. Service Portfolio
6.6.2.3. Financial Information
6.6.2.4. Manufacturing Capabilities and Facilities
6.6.2.5. Future Outlook
6.6.3. WuXi AppTec
6.6.3.1. Company Overview
6.6.3.2. Service Portfolio
6.6.3.3. Financial Information
6.6.3.4. Manufacturing Capabilities and Facilities
6.6.3.5. Recent Developments
6.6.3.6. Future Outlook
7. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
7.1. Chapter Overview
7.2. Small Molecules and Large Molecules Drugs / Therapies
7.2.1. Comparison of Key Characteristics
7.2.2. Comparison of Manufacturing Processes
7.2.3. Comparison of Key Manufacturing Challenges
7.3. Manufacturing of Large Molecules (Biologics): List of Biopharmaceutical CMOs
8. KEY INSIGHTS
8.1. Chapter Overview
8.2. Multipotentialite Service Providers: Heat Map Analysis
8.3. Pharmaceutical CMOs: Geographical Landscape
8.4. Pharmaceutical CMOs: Analysis by Geography, Company Size and Business Segment
9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Pharmaceutical Contract Manufacturing: Installed Global Capacity
9.3.1. Distribution by Size of CMOs
9.3.2. Distribution by Scale of Operation
9.3.3. Distribution by Location of Headquarters
9.3.4. Distribution by Location of Manufacturing Facilities
9.4. Concluding Remarks
10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Pharmaceutical Contract Manufacturing Market, 2018-2028
10.3.1. Pharmaceutical Contract Manufacturing Market for API Manufacturing, 2018-2028
10.3.2. Pharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2018-2028
10.4. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions
10.4.1. Pharmaceutical Contract Manufacturing Market in North America, 2018-2028
10.4.1.1. Pharmaceutical Contract Manufacturing Market in the US, 2018-2028
10.4.1.2. Pharmaceutical Contract Manufacturing Market in Canada, 2018-2028
10.4.1.3. Pharmaceutical Contract Manufacturing Market in Mexico, 2018-2028
10.4.2. Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028
10.4.2.1. Pharmaceutical Contract Manufacturing Market in Italy, 2018-2028
10.4.2.2. Pharmaceutical Contract Manufacturing Market in Germany, 2018-2028
10.4.2.3. Pharmaceutical Contract Manufacturing Market in France, 2018-2028
10.4.2.4. Pharmaceutical Contract Manufacturing Market in Spain, 2018-2028
10.4.2.5. Pharmaceutical Contract Manufacturing Market in the UK, 2018-2028
10.4.2.6. Pharmaceutical Contract Manufacturing Market in Rest of Europe, 2018-2028
10.4.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028
10.4.3.1. Pharmaceutical Contract Manufacturing Market in India, 2018-2028
10.4.3.2. Pharmaceutical Contract Manufacturing Market in China, 2018-2028
10.4.3.3. Pharmaceutical Contract Manufacturing Market in Japan, 2018-2028
10.4.3.4. Pharmaceutical Contract Manufacturing Market in Australia, 2018-2028
10.4.3.5. Pharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2018-2028
10.4.4. Pharmaceutical Contract Manufacturing Market in Rest of the World, 2018-2028
10.4.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions
10.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product
10.6. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API
10.7. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF
10.7.1. Pharmaceutical Contract Manufacturing Market for Solid Form FDF, 2018-2028
10.7.2. Pharmaceutical Contract Manufacturing Market for Injectable Form FDF, 2018-2028
10.7.3. Pharmaceutical Contract Manufacturing Market for Semi-Solid / Liquid Form FDF, 2018-2028
10.8. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form
10.8.1. Pharmaceutical Contract Manufacturing Market for Tablets / Capsules / Blister Packing, 2018-2028
10.8.2. Pharmaceutical Contract Manufacturing Market for Glass / Plastic / Dropper Bottles, 2018-2028
10.8.3. Pharmaceutical Contract Manufacturing Market for Vials / Cartridges, 2018-2028
10.8.4. Pharmaceutical Contract Manufacturing Market for Ointments / Gels / Tubes, 2018-2028
10.8.5. Pharmaceutical Contract Manufacturing Market for Ampoules, 2018-2028
10.8.6. Pharmaceutical Contract Manufacturing Market for Sachets / Pouches / Bags, 2018-2028
10.8.7. Pharmaceutical Contract Manufacturing Market for Pre-filled Syringes, 2018-2028
10.9. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers
10.10 Concluding Remarks
11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
11.6. Comparison of SWOT Factors
12. FUTURE OF THE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
12.1. Chapter Overview
12.2. Anticipated Growth in Outsourcing Activities
12.3. Growing Focus on Emerging Markets
12.4. Expansion of Capabilities and Emergence of One-Stop-Shops
12.5. Adoption of New Technologies and Focus on Innovation to Support Further Growth
12.6. Use of Big Data and Advanced Analytics to Improve Manufacturing Processes
12.7. Implementation of Cybersecurity Solutions to Safeguard Valuable Customer Data
12.8. Concluding Remarks
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Ajinomoto Althea
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Scott Goldstein, Associate Director, Drug Product Manufacturing
13.3. Bachem
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Thomas Fruh, Chief Executive Officer
13.4. Sovereign Pharma
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Piyush Desai, Director, Operations
13.5. Batavia Biosciences
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Claire Otjes, Assistant Marketing Manager
13.6. Polymun Scientific
13.6.1. Company Snapshot
13.6.2. Interview Transcript: Dietmar Katinger, Chief Executive Officer
13.7. Rentschler Biopharma
13.7.1. Company Snapshot
13.7.2. Interview Transcript: Birgit Schwab, Senior Manager Strategic Marketing
13.8. WACKER Biotech
13.8.1. Company Snapshot
13.8.2. Interview Transcript: Sebastian Schuck, Head of Business Development
13.9. CiVentiChem
13.9.1. Company Snapshot
13.9.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer
13.10. CordenPharma
13.10.1. Company Snapshot
13.10.2. Interview Transcript: Roberto Margartia, Business Development Director
13.11. Helsinn Group
13.11.1. Company Snapshot
13.11.2. Interview Transcript: Allison Vavala, Senior Manager, Business Development
13.12. Novasep
13.12.1. Company Snapshot
13.12.2. Interview Transcript: Kevin Daley, Market Director Pharmaceuticals
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Types of Manufacturers in Contract Manufacturing Industry
Figure 3.2 Types of Third-Party Service Providers in the Pharmaceutical Contract Manufacturing Industry
Figure 3.3 Outsourcing across Various Components of Pharmaceutical Value Chain
Figure 3.4 Range of Services Offered by CMOs
Figure 3.5 Factors for Selecting a CMO Partner
Figure 4.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 4.2 Pharmaceutical CMOs: Distribution by Geographical Location
Figure 4.3 Pharmaceutical CMOs: Regional Hubs
Figure 4.4 Pharmaceutical CMOs: Distribution by Company Size
Figure 4.5 Pharmaceutical CMOs: Distribution by Type of Business Segment
Figure 4.6 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Figure 4.7 Pharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.8 Pharmaceutical CMOs: Distribution by Type of Service Offering
Figure 4.9 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Figure 4.10 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Figure 5.1 Key Regulatory Requirements for CMOs and CROs in India
Figure 5.2 Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Figure 5.3 Bubble Analysis: Regional Regulatory Summary
Figure 6.1 AMRI: Service Portfolio
Figure 6.2 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 6.3 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 6.4 Catalent® Pharma Solutions: Service Portfolio
Figure 6.5 Catalent® Pharma Solutions: Annual Revenues, 2013-H1 2018 (USD Million)
Figure 6.6 DPT® Laboratories: Service Portfolio
Figure 6.7 Patheon®: Service Portfolio
Figure 6.8 Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Figure 6.9 Thermo Fisher Scientific: Revenues by Business Segments, 2017 (USD Billion)
Figure 6.10 Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 6.11 Patheon®: Revenues by Business Segments, 2016 (USD Million)
Figure 6.12 Aenova Group: Service Portfolio
Figure 6.13 Almac Group: Service Portfolio
Figure 6.14 CordenPharma: Service Portfolio
Figure 6.15 Fresenius Kabi: Service Portfolio
Figure 6.16 Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Figure 6.17 Fresenius Kabi: Revenues by Product Segments, 2017 (EUR Million)
Figure 6.18 Glatt®: Service Portfolio
Figure 6.19 Groupe SYNERLAB: Service Portfolio
Figure 6.20 Hovione: Service Portfolio
Figure 6.21 Recipharm: Service Portfolio
Figure 6.22 Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Figure 6.23 Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Figure 6.24 Siegfried: Service Portfolio
Figure 6.25 Siegfried: Annual Revenues, 2013-2017 (CHF Million)
Figure 6.26 Siegfried: Revenues by Product Segments, 2017 (CHF Million)
Figure 6.27 CMIC Group: Service Portfolio
Figure 6.28 CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Figure 6.29 Nectar Lifesciences: Service Portfolio
Figure 6.30 Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Figure 6.31 WuXi AppTec: Service Portfolio
Figure 6.32 STA Pharmaceuticals (API Service Provider, WuXi AppTec): Service Portfolio
Figure 6.33 WuXi AppTec: Revenues (USD Million)
Figure 7.1 Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 7.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Processes
Figure 7.3 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Figure 8.1 Multipotentialite Service Providers, Heat Map Analysis: Distribution by Geography, Company Size and Year of Establishment
Figure 8.2 Pharmaceutical CMOs: Geographical Landscape Analysis by Location of Manufacturing Facilities
Figure 8.3 Pharmaceutical CMOs: Distribution by Geography, Company Size and Business Segment
Figure 9.1 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Figure 9.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Figure 9.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 9.4 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Figure 9.5 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 9.6 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 10.1 Pharmaceutical Contract Manufacturing: Market Forecast Approach
Figure 10.2 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Figure 10.3 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Figure 10.4 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.5 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Figure 10.6 Pharmaceutical Contract Manufacturing Market, Share by Regions, 2018, 2028 (Volume, %)
Figure 10.7 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Base Scenario (USD Billion)
Figure 10.8 Pharmaceutical Contract Manufacturing Market, 2018-2028: US, Base Scenario (USD Billion)
Figure 10.9 Pharmaceutical Contract Manufacturing Market, 2018-2028: Canada, Base Scenario (USD Billion)
Figure 10.10 Pharmaceutical Contract Manufacturing Market, 2018-2028: Mexico, Base Scenario (USD Billion)
Figure 10.11 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Base Scenario (USD Billion)
Figure 10.12 Pharmaceutical Contract Manufacturing Market, 2018-2028: Italy, Base Scenario (USD Billion)
Figure 10.13 Pharmaceutical Contract Manufacturing Market, 2018-2028: Germany, Base Scenario (USD Billion)
Figure 10.14 Pharmaceutical Contract Manufacturing Market, 2018-2028: France, Base Scenario (USD Billion)
Figure 10.15 Pharmaceutical Contract Manufacturing Market, 2018-2028: Spain, Base Scenario (USD Billion)
Figure 10.16 Pharmaceutical Contract Manufacturing Market, 2018-2028: UK, Base Scenario (USD Billion)
Figure 10.17 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of Europe, Base Scenario (USD Billion)
Figure 10.18 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Base Scenario (USD Billion)
Figure 10.19 Pharmaceutical Contract Manufacturing Market, 2018-2028: India, Base Scenario (USD Billion)
Figure 10.20 Pharmaceutical Contract Manufacturing Market, 2018-2028: China, Base Scenario (USD Billion)
Figure 10.21 Pharmaceutical Contract Manufacturing Market, 2018-2028: Japan, Base Scenario (USD Billion)
Figure 10.22 Pharmaceutical Contract Manufacturing Market, 2018-2028: Australia, Base Scenario (USD Billion)
Figure 10.23 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of Asia-Pacific, Base Scenario (USD Billion)
Figure 10.24 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Base Scenario (USD Billion)
Figure 10.25 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Figure 10.26 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, % Share)
Figure 10.27 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Figure 10.28 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product and Regions, Base Scenario (USD Billion)
Figure 10.29 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Figure 10.30 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Figure 10.31 Pharmaceutical Contract Manufacturing Market for Solid Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.32 Pharmaceutical Contract Manufacturing Market for Injectable Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.33 Pharmaceutical Contract Manufacturing Market for Semi-Solid / Liquid Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.34 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Figure 10.35 Pharmaceutical Contract Manufacturing Market for Tablets / Capsules / Blister Packing, 2018-2028: Base Scenario (USD Billion)
Figure 10.36 Pharmaceutical Contract Manufacturing Market for Glass / Plastic / Dropper Bottles, 2018-2028: Base Scenario (USD Billion)
Figure 10.37 Pharmaceutical Contract Manufacturing Market for Vials / Cartridges, 2018-2028: Base Scenario (USD Billion)
Figure 10.38 Pharmaceutical Contract Manufacturing Market for Ointments / Gels / Tubes, 2018-2028: Base Scenario (USD Billion)
Figure 10.39 Pharmaceutical Contract Manufacturing Market for Ampoules, 2018-2028: Base Scenario (USD Billion)
Figure 10.40 Pharmaceutical Contract Manufacturing Market for Sachets / Pouches / Bags, 2018-2028: Base Scenario (USD Billion)
Figure 10.41 Pharmaceutical Contract Manufacturing Market for Pre-filled Syringes, 2018-2028: Base Scenario (USD Billion)
Figure 10.42 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Figure 10.43 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)
Figure 11.1 Pharmaceutical Contract Manufacturing SWOT Analysis: Overview
Figure 11.2 Pharmaceutical Contract Manufacturing SWOT Analysis: Strengths
Figure 11.3 Pharmaceutical Contract Manufacturing SWOT Analysis: Weaknesses
Figure 11.4 Pharmaceutical Contract Manufacturing SWOT Analysis: Opportunities
Figure 11.5 Pharmaceutical Contract Manufacturing SWOT Analysis: Threats
Figure 11.6 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 12.1 Future of Pharmaceutical Contract Manufacturing Market
Figure 12.2 Emerging Markets in Pharmaceutical Contract Manufacturing Industry
Table 4.1 Pharmaceutical CMOs: List of Industry Players
Table 4.2 Pharmaceutical CMOs: Information on Type of FDF Offered
Table 4.3 Pharmaceutical CMOs: Information on Scale of Operation
Table 4.4 Pharmaceutical CMOs: Information on Type of Service Offering
Table 4.5 Pharmaceutical CMOs: Information on Location of Manufacturing Facilities
Table 4.6 Pharmaceutical CMOs: Information on Type of Primary Packaging Form Offered
Table 5.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
Table 5.2 Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
Table 5.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
Table 6.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
Table 6.2 AMRI: Manufacturing Facilities
Table 6.3 AMRI: Sterile Manufacturing Facilities
Table 6.4 AMRI: Recent Collaborations
Table 6.5 AMRI: Recent Expansions
Table 6.6 Catalent® Pharma Solutions: Manufacturing Facilities
Table 6.7 Catalent® Pharma Solutions: Recent Collaborations
Table 6.8 Catalent® Pharma Solutions: Recent Expansions
Table 6.9 DPT® Laboratories: Manufacturing Facilities
Table 6.10 DPT® Laboratories: Recent Collaborations
Table 6.11 DPT® Laboratories: Recent Expansions
Table 6.12 Patheon®: Manufacturing Facilities
Table 6.13 Patheon®: Recent Collaborations
Table 6.14 Patheon®: Recent Expansions
Table 6.15 Aenova Group: Manufacturing Facilities
Table 6.16 Aenova Group: Drug Product Manufacturing Capabilities
Table 6.17 Aenova Group: Recent Expansions
Table 6.18 Almac Group: Recent Collaborations
Table 6.19 Almac Group: Recent Expansions
Table 6.20 CordenPharma: Manufacturing Facilities
Table 6.21 CordenPharma: Recent Collaborations
Table 6.22 CordenPharma: Recent Expansions
Table 6.23 Fresenius Kabi: Manufacturing Facilities
Table 6.24 Fresenius Kabi: Packaging Capabilities
Table 6.25 Fresenius Kabi: Recent Collaborations
Table 6.26 Fresenius Kabi: Recent Expansions
Table 6.27 Glatt®: Manufacturing Facilities
Table 6.28 Glatt®: Recent Expansions
Table 6.29 Groupe SYNERLAB: Manufacturing Facilities
Table 6.30 Hovione: Manufacturing Facilities
Table 6.31 Hovione: Recent Collaborations
Table 6.32 Hovione: Recent Expansions
Table 6.33 Recipharm: Manufacturing Facilities
Table 6.34 Recipharm: Recent Collaborations
Table 6.35 Recipharm: Recent Expansions
Table 6.36 Siegfried: Manufacturing Facilities
Table 6.37 Siegfried: Recent Collaborations
Table 6.38 CMIC Group: Manufacturing Facilities
Table 6.39 CMIC Group: Recent Collaborations
Table 6.40 CMIC Group: Recent Expansions
Table 6.41 Nectar Lifesciences: Manufacturing Facilities
Table 6.42 WuXi AppTec: Manufacturing Facilities
Table 6.43 WuXi AppTec: Recent Collaborations
Table 6.44 WuXi AppTec: Recent Expansions
Table 7.1 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 7.2 List of Biopharmaceutical CMOs
Table 9.1 Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 9.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 13.1 Ajinomoto Althea: Key Highlights
Table 13.2 Bachem: Key Highlights
Table 13.3 Sovereign Pharma: Key Highlights
Table 13.4 Batavia Biosciences: Key Highlights
Table 13.5 Polymun Scientific: Key Highlights
Table 13.6 Rentschler Biopharma: Key Highlights
Table 13.7 WACKER Biotech: Key Highlights
Table 13.8 CiVentiChem: Key Highlights
Table 13.9 Helsinn Group: Key Highlights
Table 13.10 Novasep: Key Highlights
Table 14.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Table 14.2 Pharmaceutical CMOs: Distribution by Geographical Location
Table 14.3 Pharmaceutical CMOs: Distribution by Company Size
Table 14.4 Pharmaceutical CMOs: Distribution by Type of Business Segment
Table 14.5 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Table 14.6 Pharmaceutical CMOs: Distribution by Scale of Operation
Table 14.7 Pharmaceutical CMOs: Distribution by Service Offerings
Table 14.8 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Table 14.9 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Table 14.10 Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Table 14.11 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 14.12 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 14.13 Catalent® Pharma Solutions: Annual Revenues, 2013-H1 2018 (USD Million)
Table 14.14 Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Table 14.15 Thermo Fisher Scientific: Revenues by Business Segments, 2017 (USD Billion)
Table 14.16 Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Table 14.17 Patheon®: Revenues by Business Segments, 2016 (USD Million)
Table 14.18 Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Table 14.19 Fresenius Kabi: Revenues by Product Segments, 2017 (EUR Million)
Table 14.20 Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Table 14.21 Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Table 14.22 Siegfried: Annual Revenues, 2013-2017 (CHF Million)
Table 14.23 Siegfried: Revenues by Product Segments, 2017 (CHF Million)
Table 14.24 CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Table 14.25 Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Table 14.26 WuXi AppTec: Revenues (USD Million)
Table 14.27 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Table 14.28 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Table 14.29 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 14.30 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 14.31 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Table 14.32 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 14.33 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 14.34 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Conservative Scenario (USD Billion)
Table 14.35 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Table 14.36 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.37 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Conservative Scenario (USD Billion)
Table 14.48 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Table 14.39 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.40 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Conservative Scenario (USD Billion)
Table 14.41 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Table 14.42 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.43 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Conservative Scenario (USD Billion)
Table 14.44 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Table 14.45 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Optimistic Scenario (USD Billion)
Table 14.46 Pharmaceutical Contract Manufacturing Market, Share by Regions, 2018, 2028 (Volume, %)
Table 14.47 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Conservative Scenario (USD Billion)
Table 14.48 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Base Scenario (USD Billion)
Table 14.49 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.50 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Conservative Scenario (USD Billion)
Table 14.51 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Base Scenario (USD Billion)
Table 14.52 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.53 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Conservative Scenario (USD Billion)
Table 14.54 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Base Scenario (USD Billion)
Table 14.55 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.56 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Table 14.57 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, % Share)
Table 14.58 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Conservative Scenario (USD Billion)
Table 14.59 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Table 14.60 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Types of API Product, Optimistic Scenario (USD Billion)
Table 14.61 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Conservative Scenario (USD Billion)
Table 14.62 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Base Scenario (USD Billion)
Table 14.63 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Type of API Product in North America, Optimistic Scenario (USD Billion)
Table 14.64 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Conservative Scenario (USD Billion)
Table 14.65 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Base Scenario (USD Billion)
Table 14.66 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Optimistic Scenario (USD Billion)
Table 14.67 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Conservative Scenario (USD Billion)
Table 14.68 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Base Scenario (USD Billion)
Table 14.69 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Optimistic Scenario (USD Billion)
Table 14.70 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Conservative Scenario (USD Billion)
Table 14.71 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Base Scenario (USD Billion)
Table 14.72 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Optimistic Scenario (USD Billion)
Table 14.73 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Conservative Scenario (USD Billion)
Table 14.74 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Table 14.75 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Optimistic Scenario (USD Billion)
Table 14.76 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Conservative Scenario (USD Billion)
Table 14.77 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Table 14.78 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Optimistic Scenario (USD Billion)
Table 14.79 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Conservative Scenario (USD Billion)
Table 14.80 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Table 14.81 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Optimistic Scenario (USD Billion)
Table 14.82 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Conservative Scenario (USD Billion)
Table 14.83 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Table 14.84 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Optimistic Scenario (USD Billion)
Table 14.85 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)
The following companies and organizations have been mentioned in the report:
Discounts available for multiple report purchases
sales@rootsanalysis.net
.png)
.jpg)
.png)
.png)
.jpg)
.jpg)
.jpg)
